Evidence map›Paper›PMID 34508293›Full record

ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2022

Very Early Recurrence After Liver Resection for Colorectal Metastases: Incidence, Risk Factors, and Prognostic Impact.

Luca Viganò, Damiano Gentile, Jacopo Galvanin, Pio Corleone, Guido Costa, Matteo Cimino, Fabio Procopio, Guido Torzilli

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Proteomic Profiling and Biomarker Discovery in Colorectal Liver Metastases.International journal of molecular sciences · 2022
    Review
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Luca ViganòDivision of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, via Manzoni 56 20089, Rozzano, Milan, Italy.
Damiano GentileDivision of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, via Manzoni 56 20089, Rozzano, Milan, Italy.
Jacopo GalvaninDivision of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, via Manzoni 56 20089, Rozzano, Milan, Italy.
Pio CorleoneDivision of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, via Manzoni 56 20089, Rozzano, Milan, Italy.
Guido CostaDivision of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, via Manzoni 56 20089, Rozzano, Milan, Italy.
Matteo CiminoDivision of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, via Manzoni 56 20089, Rozzano, Milan, Italy.
Fabio ProcopioDivision of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, via Manzoni 56 20089, Rozzano, Milan, Italy.
Guido TorzilliDivision of Hepatobiliary and General Surgery, Department of Surgery, IRCCS Humanitas Research Hospital, via Manzoni 56 20089, Rozzano, Milan, Italy. guido.torzilli@hunimed.eu.ORCID http://orcid.org/0000-0001-5798-5021

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLiver resection for colorectal metastases is affected by a non-negligible recurrence rate. The earlier the recurrence, the worse the prognosis. We analyzed an unexplored topic, i.e., the incidence, predictive factors, and prognostic impact of very early recurrence (≤ 3 months after hepatectomy).

methodsAll consecutive liver resections for colorectal metastases performed between 2004 and 2017 were retrospectively reviewed. Inclusion criteria were available recurrence status at 3 months after resection and follow-up ≥ 12 months.

resultsOverall, 484 patients were analyzed; 56 (11.6%) had very early recurrence. Independent predictors were number of metastases (very early recurrence in 3.7% of patients with solitary metastasis, 8.1% of those with 2-9 metastases; 20.0% of those with 10-14 metastases; 44.4% of those with ≥ 15 metastases, p < 0.001) and extrahepatic disease (very early recurrence in 23.2% of patients with vs. 10.1% of those without extrahepatic disease, p = 0.017). Very early recurrence rate in patients with ≥ 15 metastases and simultaneous extrahepatic disease was 71.4%. Patients with very early recurrence had poor survival (5-year survival 17.3% vs. 44.5% of non-very early recurrence patients, p < 0.001), worse than patients with 3-to-6 months recurrence (p = 0.070), and no different from unresected patients (p = 0.114). Fifteen patients with very early recurrence (26.8%) underwent repeated treatment with adequate survival (at 3 years 42.2%), but seven had a further recurrence within 3 months.

conclusionsVery early recurrence occurs in about 12% of patients undergoing aggressive surgery for colorectal metastases. The risk is increased in patients with numerous metastases or extrahepatic disease. Very early recurrence is associated with very poor prognosis, similar to that of unresected patients, and a low chance of effective repeated treatment.

Indexed as

Colorectal NeoplasmsLiver NeoplasmsHepatectomyHumansIncidenceNeoplasm Recurrence, LocalPrognosisRetrospective StudiesRisk FactorsSurvival RateEarly recurrenceExtrahepatic metastasesLiver surgery for colorectal metastasesOverall survivalProgression-free survival

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.